V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20213815 | 20129521 | 1.69 | 64.8 | Adjuvant (A) | 2016-10-29 | 2018-03-17 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101652283 |
| 20213816 | 20129522 | 1.56 | 80 | Palliative (P) | 2018-12-25 | 2018-12-25 | Capecitabine 35days + RT | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100601314 |
| 20213820 | 20129523 | 1.62 | 82.5 | Curative (C) | 2016-03-07 | 2016-03-20 | EOX | 02 | null | EOX | 101257716 |
| 20213821 | 20129524 | null | 43 | Palliative (P) | 2018-06-15 | 2018-08-05 | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 02 | 2 | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101715850 |
| 20213822 | 20129525 | null | 80.5 | Palliative (P) | 2016-08-10 | 2016-09-29 | Oxaliplatin + Raltitrexed | 99 | Y | OXALIPLATIN + RALTITREXED | 101583712 |
| 20213824 | 20129526 | 1.64 | 77.6 | Palliative (P) | 2020-02-07 | 2020-04-10 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101694751 |
| 20213825 | 20129527 | 1.93 | 82 | Palliative (P) | 2019-11-29 | 2019-12-20 | EOX | N | N | CETUXIMAB + IRINOTECAN + MDG | 100444315 |
| 20213830 | 20129528 | 1.9 | 74.9 | Palliative (P) | 2017-02-05 | 2018-02-01 | Trial Unspecified | 02 | N | CAPECITABINE + RT | 101035103 |
| 20213836 | 20129529 | 1.52 | null | null | 2016-09-16 | 2016-11-11 | EOX | 02 | N | OXALIPLATIN + RALTITREXED | 100354298 |
| 20213838 | 20129530 | 1.84 | 136 | 03 | 2018-05-04 | 2018-05-14 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + IRINOTECAN + MDG | 101210753 |
| 20213839 | 20129531 | 1.69 | 90.9 | Palliative (P) | 2016-12-16 | 2016-12-22 | Sorafenib | 02 | N | SORAFENIB | 101318907 |
| 20213840 | 20129532 | 0 | 66 | Adjuvant (A) | 2019-11-25 | 2019-11-25 | Oxaliplatin + Raltitrexed | 02 | null | OXALIPLATIN + RALTITREXED | 100212374 |
| 20213842 | 20129533 | 1.62 | 77.8 | Curative (C) | 2019-08-04 | 2019-08-19 | EOX | 02 | Y | CETUXIMAB + IRINOTECAN + MDG | 100632172 |
| 20213844 | 20129534 | 1.72 | 46.8 | Palliative (P) | 2020-01-06 | 2020-01-06 | IRINOTECAN + MDG + PANITUMUMAB | 02 | null | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101203329 |
| 20213850 | 20129535 | 1.75 | 100.6 | Curative (C) | 2018-11-24 | 2018-11-30 | Sorafenib | 02 | null | SORAFENIB | 101759865 |
| 20213854 | 20129536 | 1.66 | 56.4 | Adjuvant (A) | null | 2018-05-18 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 101589466 |
| 20213855 | 20129537 | 1.6 | 95.4 | Neo-adjuvant (N) | 2019-08-17 | 2019-12-08 | Trial Unspecified | 02 | Y | TRIAL | 101555883 |
| 20213858 | 20129538 | 1.78 | 91.5 | Curative (C) | 2018-02-07 | 2018-03-04 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100599641 |
| 20213859 | 20129539 | 1.88 | 81.6 | 03 | 2018-01-23 | 2018-01-30 | Sorafenib | 02 | Y | SORAFENIB | 101276690 |
| 20213860 | 20129540 | 1.72 | 69.6 | Palliative (P) | null | 2019-10-27 | Trial Unspecified | 99 | N | TRIAL | 101660189 |
| 20213861 | 20129541 | 1.7 | 73.3 | Palliative (P) | 2021-02-10 | 2021-02-14 | EOX | 99 | N | EOX | 100836532 |
| 20213865 | 20129542 | 1.76 | 50.2 | null | 2020-03-27 | 2020-04-22 | CAPECITABINE + RT | 02 | null | CAPECITABINE + RT | 101450607 |
| 20213867 | 20129543 | 1.81 | 94 | Neo-adjuvant (N) | 2018-02-18 | 2018-03-16 | Sorafenib | 02 | N | SORAFENIB | 100055309 |
| 20213868 | 20129544 | 1.78 | 92.8 | Adjuvant (A) | 2017-01-03 | 2017-01-04 | Cetuximab + Oxaliplatin + MdG Maint | 02 | Y | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100329853 |
| 20213870 | 20129545 | 1.44 | 69.4 | Neo-adjuvant (N) | 2018-09-06 | 2018-11-29 | Oxaliplatin + Raltitrexed | 02 | null | OXALIPLATIN + RALTITREXED | 101413320 |
| 20213871 | 20129546 | 1.55 | 91.8 | Adjuvant (A) | 2015-03-24 | 2015-04-02 | EOX | N | N | OXALIPLATIN + RALTITREXED | 101519771 |
| 20213872 | 20129547 | 1.6 | 40.6 | Palliative (P) | 2021-02-23 | 2021-03-18 | Oxaliplatin + Raltitrexed | 2 | N | CETUXIMAB + IRINOTECAN + MDG | 100502387 |
| 20213874 | 20129548 | 1.66 | 90 | Curative (C) | 2017-12-19 | 2018-05-07 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100979693 |
| 20213876 | 20129549 | 1.69 | 75.6 | Neo-adjuvant (N) | 2018-12-01 | 2018-12-07 | Cetuximab + FOLFIRI cycle 2 onwards | Y | null | CETUXIMAB + IRINOTECAN + MDG | 101468581 |
| 20213877 | 20129550 | 1.6 | 129.2 | Adjuvant (A) | 2013-09-15 | 2013-09-21 | Cetuximab + FOLFIRI cycle 2 onwards | N | N | CETUXIMAB + IRINOTECAN + MDG | 101478941 |
| 20213879 | 20129551 | 1.78 | 64 | Curative (C) | 2018-12-12 | 2019-02-19 | EOX | 02 | N | SORAFENIB | 101830755 |
| 20213882 | 20129552 | 0 | 74.9 | null | 2016-06-08 | 2016-11-29 | CAPECITABINE + RT | 02 | N | CAPECITABINE + RT | 101227921 |
| 20213885 | 20129553 | 1.74 | 65 | Neo-adjuvant (N) | 2016-04-14 | 2016-04-17 | EOX | N | Y | TRIAL | 101257790 |
| 20213887 | 20129554 | 1.61 | 64.4 | Palliative (P) | 2019-09-13 | 2019-09-16 | EOX | Y | N | TRIAL | 100962054 |
| 20213888 | 20129555 | 1.6 | 68.5 | 03 | null | 2021-02-08 | Sorafenib | 02 | N | SORAFENIB | 100088430 |
| 20213889 | 20129556 | 1.85 | 64.2 | Palliative (P) | 2020-08-30 | 2020-09-06 | Cetuximab + Oxaliplatin + MdG Maint | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101379461 |
| 20213894 | 20129557 | 1.88 | 63 | null | 2018-10-02 | 2018-11-07 | Cetuximab + Oxaliplatin + MdG Load | 02 | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100417374 |
| 20213895 | 20129558 | 1.78 | 57 | Palliative (P) | 2019-11-25 | 2019-11-25 | Cetuximab + FLUOROURACIL + OXALIPLATIN | 02 | null | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101615898 |
| 20213899 | 20129559 | 1.67 | 103 | Palliative (P) | 2016-06-16 | 2016-07-14 | EOX | 02 | N | EOX | 100449925 |
| 20213902 | 20129560 | 1.7 | 63 | null | 2019-05-11 | 2020-02-09 | Trial Unspecified | 02 | null | TRIAL | 100370319 |
| 20213903 | 20129561 | 1.85 | 0 | Curative (C) | 2020-10-01 | 2020-10-09 | Trial Unspecified | N | null | TRIAL | 101790252 |
| 20213904 | 20129562 | 1.7 | 75.2 | Palliative (P) | 2017-08-25 | 2017-08-30 | EOX | 02 | Y | OXALIPLATIN + RALTITREXED | 101225462 |
| 20213906 | 20129563 | 1.7 | 79.6 | Palliative (P) | 2019-01-11 | 2019-02-06 | Cetuximab + FOLFIRI cycle 2 onwards | N | N | CETUXIMAB + IRINOTECAN + MDG | 100452246 |
| 20213907 | 20129564 | 1.78 | 107 | Palliative (P) | 2017-11-02 | 2017-11-20 | EOX | 02 | N | OXALIPLATIN + RALTITREXED | 100065102 |
| 20213908 | 20129565 | 0 | 86.8 | null | 2018-11-16 | 2018-11-26 | Cetuximab + FLUOROURACIL + OXALIPLATIN | 02 | null | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100423714 |
| 20213913 | 20129566 | 1.57 | 75.3 | null | 2018-11-14 | 2018-12-11 | EOX | 02 | Y | EOX | 101430188 |
| 20213914 | 20129567 | 1.81 | 92 | null | 2018-08-09 | 2018-09-06 | Sorafenib | 02 | N | SORAFENIB | 100786720 |
| 20213918 | 20129568 | 0 | 75.4 | Palliative (P) | 2019-06-14 | 2019-09-07 | Cetuximab + FOLFIRI cycle 2 onwards | N | N | TRIAL | 101506247 |
| 20213920 | 20129569 | 1.78 | 64.5 | Neo-adjuvant (N) | 2018-02-13 | 2018-03-05 | EOX | 01 | N | TRIAL | 101097155 |
| 20213921 | 20129570 | 1.52 | 47 | Palliative (P) | 2017-10-02 | 2017-10-16 | Trial Unspecified | N | N | TRIAL | 101809154 |